Precigen (PGEN) Stock Price, News & Analysis

Company Overview

Precigen, Inc. (NASDAQ:PGEN) is a clinical-stage biopharmaceutical company focused on developing gene and cell therapies for serious diseases, including cancer, infectious diseases and certain immune-related conditions. The company uses its proprietary technologies to engineer therapies intended to improve treatment precision, durability and accessibility.

Precigen’s pipeline has included PRGN-2012, an investigational immunotherapy for recurrent respiratory papillomatosis, as well as programs based on its UltraCAR-T platform for cancer treatment. The company has also developed additional gene- and cell-therapy candidates using engineered viral vectors and other biologic delivery technologies.

Precigen was formerly known as Intrexon Corporation and adopted its current name in 2020. The company is headquartered in Germantown, Maryland, and conducts its research and clinical-development activities primarily in the United States. Helen Sabzevari serves as Precigen’s president and chief executive officer.

Key Stats

• Today's Range: $7.42 to $7.70
• 50-Day Range: $6.10 to $8.56
• 52-Week Range: $3.04 to $8.98
• Volume: 1.90 million shs
• Average Volume: 4.68 million shs
• Market Capitalization: $2.70 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $13.67
• Consensus Rating: Moderate Buy

Precigen Stock Analysis - MarketRank™

Precigen scored higher than 73% of companies evaluated by MarketBeat, and ranked 188th out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.1 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Precigen has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 4 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Precigen has a consensus price target of $13.67, representing about 78.8% upside from its current price of $7.64.

Amount of Analyst Coverage

Precigen has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 204.17%

Earnings Growth

Earnings for Precigen are expected to grow by 204.17% in the coming year, from $0.24 to $0.73 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Precigen is -7.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Precigen is -7.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Precigen has a P/B Ratio of 127.40. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

22.76% of the float of Precigen has been sold short.

Short Interest Ratio / Days to Cover

Precigen has a short interest ratio ("days to cover") of 7.38.

Change versus previous month

Short interest in Precigen has recently increased by 12.46%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Precigen does not currently pay a dividend.

Dividend Growth

Precigen does not have a long track record of dividend growth.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: -0.02

News Sentiment

Precigen has a news sentiment score of -0.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.71 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Precigen this week, compared to 4 articles on an average week.

Search Interest

17 people have searched for PGEN on MarketBeat in the last 30 days. This is an increase of 89% compared to the previous 30 days.

MarketBeat Follows

4 people have added Precigen to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Precigen insiders have sold 11,259.61% more of their company's stock than they have bought. Specifically, they have bought $24,662.00 in company stock and sold $2,801,508.00 in company stock.

Percentage Held by Insiders

41.40% of the stock of Precigen is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

33.51% of the stock of Precigen is held by institutions.

Company Calendar

• Last Earnings: 8/04/2026
• Today: 10/14/2026
• Next Earnings (Estimated): 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:PGEN
• CIK: 1356090
• Web: www.precigen.com
• Phone: (301) 556-9900
• Fax: N/A
• Employees: 47
• Year Founded: 1998

Price Target and Rating

• Average Price Target for Precigen: $13.67
• High Price Target: $18.00
• Low Price Target: $11.00
• Potential Upside/Downside: +80.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.04)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 31.60
• P/E Growth: N/A
• Net Income: -$250.64 million
• Net Margins: -183.98%
• Pretax Margin: -183.98%
• Return on Equity: 423.75%
• Return on Assets: 84.39%

Debt

• Debt-to-Equity Ratio: 2.15
• Current Ratio: 4.58
• Quick Ratio: 3.89

Sales & Book Value

• Annual Sales: $9.68 million
• Price / Sales: 279.35
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.06 per share
• Price / Book: 126.42

Miscellaneous

• Outstanding Shares: 356,510,000
• Free Float: 208,915,000
• Market Cap: $2.70 billion
• Optionable: Optionable
• Beta: 0.92